Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers [5]

Annals of Oncology

Volumn 18, Issue 7, 2007, Pages 1285-1286

  Bidard, F C ^a   Conforti, R ^a,b   Boulet, T ^c   Michiels, S ^c   Delaloge, S ^a,c   André, Fabrice ^a,b  

^a Department of Medical Oncology ^*  (France)

^b UPRES EA03535   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; BREAST CANCER; CANCER GRADING; CLINICAL TRIAL; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PHENOTYPE; PRIORITY JOURNAL; TISSUE MICROARRAY;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PHENOTYPE; RECEPTOR, ERBB-3; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 34547852260     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm360     Document Type: Letter

References (4)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271.
3. Brenton JD, Carey LA, Ahmed AA et al. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005; 23: 7350-7360.
4. Conforti R, Boulet T, Tomasic G et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: A biomarker study from two randomized trials Ann Oncol 2007: Doi:10.1093/annonc/mdm209.